Oppenheimer Asset Management Inc. Takes Position in Illumina, Inc. $ILMN

Oppenheimer Asset Management Inc. purchased a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the second quarter, Holdings Channel.com reports. The institutional investor purchased 9,498 shares of the life sciences company’s stock, valued at approximately $1,670,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Insight Wealth Strategies LLC acquired a new position in Illumina during the 2nd quarter worth $6,062,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new stake in shares of Illumina in the 2nd quarter worth about $223,000. FNY Investment Advisers LLC raised its stake in shares of Illumina by 30.0% in the 2nd quarter. FNY Investment Advisers LLC now owns 650 shares of the life sciences company’s stock valued at $114,000 after purchasing an additional 150 shares in the last quarter. Elevation Wealth Partners LLC raised its stake in shares of Illumina by 52.5% in the 2nd quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock valued at $43,000 after purchasing an additional 84 shares in the last quarter. Finally, PensionDanmark Pensionsforsikringsaktieselskab lifted its position in shares of Illumina by 9.0% during the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 37,664 shares of the life sciences company’s stock worth $6,622,000 after purchasing an additional 3,100 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Citigroup lifted their price target on Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a research note on Monday, August 3rd. Barclays upped their price objective on Illumina from $145.00 to $160.00 and gave the company an “underweight” rating in a research note on Friday, July 31st. Zacks Research raised Illumina from a “hold” rating to a “strong-buy” rating in a report on Monday, August 3rd. TD Cowen lifted their target price on Illumina from $192.00 to $210.00 and gave the stock a “hold” rating in a research report on Friday, July 31st. Finally, Sanford C. Bernstein reiterated a “market perform” rating and issued a $215.00 price target on shares of Illumina in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $188.40.

Illumina Stock Performance

NASDAQ ILMN opened at $190.89 on Monday. Illumina, Inc. has a one year low of $88.00 and a one year high of $207.00. The company has a 50-day simple moving average of $183.78 and a 200-day simple moving average of $150.54. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. The firm has a market capitalization of $28.82 billion, a PE ratio of 35.61, a price-to-earnings-growth ratio of 2.69 and a beta of 1.44.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities analysts forecast that Illumina, Inc. will post 5.36 earnings per share for the current year.

Insider Buying and Selling

In related news, SVP Patricia Leckman sold 783 shares of the company’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $162.59, for a total transaction of $127,307.97. Following the completion of the transaction, the senior vice president directly owned 21,259 shares in the company, valued at $3,456,500.81. This represents a 3.55% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Scott M. Davies sold 615 shares of the stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $200.00, for a total value of $123,000.00. Following the completion of the sale, the insider directly owned 20,338 shares in the company, valued at $4,067,600. This represents a 2.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,415,351 shares of company stock valued at $255,966,311 over the last quarter. Company insiders own 2.90% of the company’s stock.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.